Asan Medical Center
Seoul, 138-736, South Korea
NCT Number: NCT00772811
Allogeneic Non-Myeloablative Stem Cell Transplantation Using Fludarabine and Melphalan Conditioning Regimen for Chronic Lymphocytic Leukemia, Lymphoma, and Multiple Myeloma
Looking for future studies?
Notify Me15 year–65 year
All sexes
Interventional
Phase 2
Seoul, 138-736, South Korea
Treatment plan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Fludara-Alkaran
Time frame: 9years
-To evaluate engraftment, chimerism, toxicity, incidence of acute graft-versus-host disease (GVHD), and day 100 treatment-related mortality (TRM) following allogeneic nonmyeloablative stem cell transplantation using fludarabine and melphalan conditioning regimen in patients with chronic lymphocytic leukemia (CLL), lymphoma, and multiple myeloma.
Time frame: 9years
-The secondary objectives include tumor response, incidence of chronic GVHD, and immune reconstitution.
Cooperative Study Group A for Hematology
Network
Allogeneic Non-Myeloablative Stem Cell Transplantation Using Fludarabine and Melphalan Conditioning Regimen for Chronic Lymphocytic Leukemia, Lymphoma, and Multiple Myeloma
Acronym: Flu-Mel
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03524235
Blood Protein Disorders, CLL
Los Angeles, California, United States
View Trial DetailsNCT02593123
Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia
Richmond, Virginia, United States
View Trial DetailsNCT00309842
Acute Lymphocytic Leukemia, Acute Myeloid Leukemia
Minneapolis, Minnesota, United States
View Trial DetailsNCT00036023
Blood Protein Disorders, Breast Diseases
View Trial Details